Multiple system atrophy

Goh, Yee Yen; Saunders, Emma; Pavey, Samantha; Rushton, Emma; Quinn, Niall; Houlden, Henry; Chelban, Viorica

doi:10.1136/pn-2020-002797

Cited by 9 publications

(3 citation statements)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[19][20][21] Therefore, measurements of postvoid bladder residual volume and lying/standing blood pressure are essential. 22 Brain magnetic resonance imaging (MRI) is the gold standard imaging technique for MSA and can reveal numerous abnormalities, including atrophy of various brain regions. [23][24][25][26] Diffusion-weighted imaging, magnetic resonance volumetry, and functional brain MRI are other valuable techniques for diagnosing and monitoring MSA.…”

Section: Introductionmentioning

confidence: 99%

“…Autonomic dysfunction is a frequent feature of MSA, with common complaints including orthostatic hypotension, neurogenic bladder, and constipation 19–21 . Therefore, measurements of postvoid bladder residual volume and lying/standing blood pressure are essential 22 …”

Section: Introductionmentioning

confidence: 99%

“… 19 , 20 , 21 Therefore, measurements of postvoid bladder residual volume and lying/standing blood pressure are essential. 22 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The potential of phosphorylated α‐synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy

Abdul‐Rahman,

Herrera‐Calderón,

Ahluwalia

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

IntroductionMultiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by the presence of glial cytoplasmic inclusions (GCIs) containing aggregated α‐synuclein (α‐Syn). Accurate diagnosis and monitoring of MSA present significant challenges, which can lead to potential misdiagnosis and inappropriate treatment. Biomarkers play a crucial role in improving the accuracy of MSA diagnosis, and phosphorylated α‐synuclein (p‐syn) has emerged as a promising biomarker for aiding in diagnosis and disease monitoring.MethodsA literature search was conducted on PubMed, Scopus, and Google Scholar using specific keywords and MeSH terms without imposing a time limit. Inclusion criteria comprised various study designs including experimental studies, case‐control studies, and cohort studies published only in English, while conference abstracts and unpublished sources were excluded.ResultsIncreased levels of p‐syn have been observed in various samples from MSA patients, such as red blood cells, cerebrospinal fluid, oral mucosal cells, skin, and colon biopsies, highlighting their diagnostic potential. The α‐Syn RT‐QuIC assay has shown sensitivity in diagnosing MSA and tracking its progression. Meta‐analyses and multicenter investigations have confirmed the diagnostic value of p‐syn in cerebrospinal fluid, demonstrating high specificity and sensitivity in distinguishing MSA from other neurodegenerative diseases. Moreover, combining p‐syn with other biomarkers has further improved the diagnostic accuracy of MSA.ConclusionThe p‐syn stands out as a promising biomarker for MSA. It is found in oligodendrocytes and shows a correlation with disease severity and progression. However, further research and validation studies are necessary to establish p‐syn as a reliable biomarker for MSA. If proven, p‐syn could significantly contribute to early diagnosis, disease monitoring, and assessing treatment response.

show abstract